AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11197282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 11197282 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (all doses)
Number of subjects: 318
Study 9537489 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG CPS antibodies against serotypes Ia, II and III
Number of subjects: 321
Study 9537489 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM antibodies against serotype III CPS
Number of subjects: 321
Study 8023538 — intervention group
Group type: EXPERIMENTAL
Intervention: Taprostene (T) at a continuous infusion of 25 ng/kg/min (in one case 12.5 ng/kg/min)
Number of subjects: 12
Study 8023538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2486180 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin serum levels determined only if renal dysfunction evident or if patient failed to respond to therapy
Number of subjects: 60
Study 2486180 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin serum levels determined after the third dose
Number of subjects: 60
Study 868906 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 53
Study 868906 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 53
Study 30303859 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-elastography
Number of subjects: 100
Study 30303859 — intervention group
Group type: COMPARATOR
Intervention: EBUS
Number of subjects: 100
Study 28875868 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling as part of a multi-domain lifestyle intervention
Number of subjects: 1260
Study 28875868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counselling)
Number of subjects: 1260
Study 25554551 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated lateral rotation
Number of subjects: 15
Study 25554551 — intervention group
Group type: COMPARATOR
Intervention: Manual lateral rotation
Number of subjects: 15
Study 25554551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 24074675 — intervention group
Group type: EXPERIMENTAL
Intervention: Packing Group (PG)
Number of subjects: 100
Study 24074675 — intervention group
Group type: COMPARATOR
Intervention: Non-Packing Group (NPG)
Number of subjects: 100
Study 20826212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral on-stimulation
Number of subjects: 22
Study 20826212 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral right-stimulation
Number of subjects: 22
Study 20826212 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral left-stimulation
Number of subjects: 22
Study 20826212 — intervention group
Group type: COMPARATOR
Intervention: Bilateral off-stimulation
Number of subjects: 22
Study 19336730 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 2035
Study 19336730 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 2035
Study 19336730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2035
Study 16771869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Mycophenolate Mofetil (FK group)
Number of subjects: 117
Study 16771869 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A + Mycophenolate Mofetil (CsA group)
Number of subjects: 117
Study 15090835 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal HIV-1 RNA level at or close to delivery
Number of subjects: 574
Study 12193262 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight‐line incisal access cavity
Number of subjects: 30
Study 12193262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual cingulum access cavity
Number of subjects: 30
Study 12193262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual conventional access cavity
Number of subjects: 30
Study 12193262 — intervention group
Group type: COMPARATOR
Intervention: All access cavity types
Number of subjects: 30
Study 9428939 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention program including mass health education, nutrition education, antismoking propaganda, detection and treatment of hypertension, diabetes, and hyperlipidemia.
Number of subjects: 3585
Study 9428939 — intervention group
Group type: COMPARATOR
Intervention: Control area with no intervention activities.
Number of subjects: 3585
Study 8491161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish diet (170 g daily for 6 weeks)
Number of subjects: 18
Study 8491161 — intervention group
Group type: COMPARATOR
Intervention: White fish diet (170 g daily for 6 weeks)
Number of subjects: 18
Study 3326423 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (7.5 mg single dose)
Number of subjects: 40
Study 3326423 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Scopolamine
Number of subjects: 40
Study 29223745 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg per day) plus fulvestrant (500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles)
Number of subjects: 432
Study 29223745 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles)
Number of subjects: 432
Study 29223745 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib
Number of subjects: 432
Study 29223745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 27611319 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples counseling
Number of subjects: 1247
Study 27611319 — intervention group
Group type: EXPERIMENTAL
Intervention: Women-only counseling
Number of subjects: 1247
Study 27611319 — intervention group
Group type: COMPARATOR
Intervention: No counseling
Number of subjects: 1247
Study 24860968 — intervention group
Group type: EXPERIMENTAL
Intervention: New and existing pharmacological strategies for constipation treatment
Number of subjects: 0
Study 22666791 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 12
Study 22666791 — intervention group
Group type: COMPARATOR
Intervention: Nasal Dilator Strips
Number of subjects: 12
Study 20466431 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐EPA (1g/day)
Number of subjects: 25
Study 20466431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20466431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (E‐EPA and Placebo)
Number of subjects: 25
Study 19038712 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour pain pump with 0.375% ropivacaine infusion at a continuous rate of 5 mL/h
Number of subjects: 50
Study 19038712 — intervention group
Group type: COMPARATOR
Intervention: No pain pump
Number of subjects: 50
Study 19038712 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour pain pump with 0.375% ropivacaine infusion
Number of subjects: 50
Study 16869138 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented feedback training program
Number of subjects: 18
Study 16869138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 18
Study 14569241 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravascular lung density (ELD) measurement using SPECT imaging
Number of subjects: 13
Study 14569241 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise ELD measurement
Number of subjects: 13
Study 10749259 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging at 0.2 T
Number of subjects: 90
Study 10749259 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging at 1.5 T
Number of subjects: 90
Study 10749259 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer variability
Number of subjects: 90
Study 10749259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer variability
Number of subjects: 90
Study 8843991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral riboflavin (20, 40, 60 mg)
Number of subjects: 0
Study 8843991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral riboflavin (40 mg) in female patients with liver cirrhosis
Number of subjects: 0
Study 8843991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous riboflavin (11.6 mg)
Number of subjects: 0
Study 8843991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral riboflavin (various doses)
Number of subjects: 0
Study 8843991 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy females
Number of subjects: 0
Study 8843991 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of peak concentrations and areas under the plasma curves
Number of subjects: 0
Study 1536412 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% albumin
Number of subjects: 2
Study 1536412 — intervention group
Group type: COMPARATOR
Intervention: Synthetic colloid, polygeline
Number of subjects: 2
Study 6486245 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 50
Study 30772370 — intervention group
Group type: EXPERIMENTAL
Intervention: Warnings including health effects
Number of subjects: 1360
Study 30772370 — intervention group
Group type: EXPERIMENTAL
Intervention: Warnings including nutrient disclosures
Number of subjects: 1360
Study 30772370 — intervention group
Group type: EXPERIMENTAL
Intervention: Warnings with the marker word 'WARNING'
Number of subjects: 1360
Study 30772370 — intervention group
Group type: EXPERIMENTAL
Intervention: Warnings with octagon shape
Number of subjects: 1360
Study 30772370 — intervention group
Group type: COMPARATOR
Intervention: Warnings with health effects and nutrient disclosures
Number of subjects: 1360
Study 30772370 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (fear and thinking about harms)
Number of subjects: 1360
Study 29579580 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Stress Echocardiography (ESE)
Number of subjects: 385
Study 29579580 — intervention group
Group type: COMPARATOR
Intervention: Exercise Electrocardiography (Ex‐ECG)
Number of subjects: 385
Study 29579580 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint (death, myocardial infarction, unplanned revascularization, hospitalization for chest pain)
Number of subjects: 385
Study 27296860 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise for 15 weeks, twice per week.
Number of subjects: 51
Study 27296860 — intervention group
Group type: COMPARATOR
Intervention: Dynamic contractions (knee extension) performed during the study.
Number of subjects: 51
Study 24841327 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model for COPD based on routinely collected data
Number of subjects: 728658
Study 24841327 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model for COPD
Number of subjects: 728658
Study 21821826 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intermittent hypoxia (AIH)
Number of subjects: 13
Study 21821826 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure to room air
Number of subjects: 13
Study 20160722 — intervention group
Group type: EXPERIMENTAL
Intervention: Current bisphosphonate users
Number of subjects: 5911
Study 20160722 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing duration of bisphosphonate use
Number of subjects: 5911
Study 20160722 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese women
Number of subjects: 5911
Study 19112384 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + 100mg trazodone
Number of subjects: 20
Study 19112384 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 20
Study 15777362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 6
Study 15777362 — intervention group
Group type: COMPARATOR
Intervention: Routine Clinical Care (RCC)
Number of subjects: 6
Study 12223247 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving remediation techniques emphasizing intrinsic motivation, contextualization, personalization, and control of learning activities.
Number of subjects: 0
Study 12223247 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving remediation techniques
Number of subjects: 0
Study 11783223 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy combined with Chinese herbal medicine (CHM)
Number of subjects: 101
Study 11783223 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy alone (Control)
Number of subjects: 101
Study 9052030 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide bleaching system
Number of subjects: 0
Study 9052030 — intervention group
Group type: COMPARATOR
Intervention: Home bleaching system
Number of subjects: 0
Study 2403697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 118
Study 2403697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 871187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatoduodenectomy
Number of subjects: 7
Study 30590810 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-delivered Acceptance and Commitment Therapy (ACT)
Number of subjects: 450
Study 30590810 — intervention group
Group type: COMPARATOR
Intervention: Group-delivered Cognitive Behavioral Therapy (CBT)
Number of subjects: 450
Study 31318868 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Regulation Strategy Development (SRSD) instruction
Number of subjects: 370
Study 31318868 — intervention group
Group type: EXPERIMENTAL
Intervention: SRSD plus Self-Regulated Learning (SRL) program using a story-tool
Number of subjects: 370
Study 31318868 — intervention group
Group type: COMPARATOR
Intervention: Week-journals
Number of subjects: 370
Study 31318868 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 370
Study 27873152 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart (faster aspart)
Number of subjects: 30
Study 27873152 — intervention group
Group type: COMPARATOR
Intervention: Insulin Aspart (IAsp)
Number of subjects: 30
Study 25142778 — intervention group
Group type: EXPERIMENTAL
Intervention: Laropiprant 100mg once daily for 4 weeks
Number of subjects: 30
Study 25142778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23437385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS) applied to M1
Number of subjects: 16
Study 23437385 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 16
Study 22134570 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine
Number of subjects: 70
Study 22134570 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine
Number of subjects: 70
Study 19243886 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ligature of DVC (SLDVC)
Number of subjects: 60
Study 19243886 — intervention group
Group type: COMPARATOR
Intervention: Standard ligature of DVC
Number of subjects: 60
Study 19243886 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 16380237 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (quetiapine, olanzapine, risperidone, clozapine)
Number of subjects: 0
Study 16380237 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotics (haloperidol, chlorpromazine)
Number of subjects: 0
Study 14725594 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN alpha) immunotherapy
Number of subjects: 0
Study 11240088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral return-to-work program
Number of subjects: 72
Study 11240088 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 72
Study 9769277 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms inhaled 15 min prior to L-ASA challenge)
Number of subjects: 10
Study 9769277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inhaled 15 min prior to L-ASA challenge)
Number of subjects: 10
Study 7508697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms/kg
Number of subjects: 3
Study 7508697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 900 micrograms/kg
Number of subjects: 3
Study 7508697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1200 micrograms/kg
Number of subjects: 3
Study 2826714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) followed by mitomycin, lomustine, and methotrexate (MCM) on progression (sequential)
Number of subjects: 108
Study 2826714 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) alternating with mitomycin, lomustine, and methotrexate (MCM) (alternating)
Number of subjects: 108
Study 31416695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump On (50% basal insulin at exercise onset)
Number of subjects: 12
Study 31416695 — intervention group
Group type: COMPARATOR
Intervention: Pump Off (0% basal insulin at exercise onset)
Number of subjects: 12
Study 30194668 — intervention group
Group type: EXPERIMENTAL
Intervention: MoVo‐LISA intervention group (IG)
Number of subjects: 83
Study 30194668 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 83
Study 28347256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (1 night of total sleep deprivation)
Number of subjects: 32
Study 28347256 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep control night
Number of subjects: 32
Study 25554993 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based preventive program adjunctive to usual pharmacological management
Number of subjects: 233
Study 25554993 — intervention group
Group type: COMPARATOR
Intervention: Attention control treatment (directing subjects to healthy living websites)
Number of subjects: 233
Study 23877341 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT (intra‐operative radiotherapy with Intrabeam(®))
Number of subjects: 342
Study 23877341 — intervention group
Group type: COMPARATOR
Intervention: Conventional external beam radiotherapy (EBRT)
Number of subjects: 342
Study 21978765 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC) - gemcitabine 1,000 mg/m² on days 1 and 8, plus carboplatin AUC 5 on day 1, every 21 days for up to six cycles.
Number of subjects: 919
Study 21978765 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC) - paclitaxel 175 mg/m² plus carboplatin AUC 6 on day 1, every 21 days for up to six cycles.
Number of subjects: 919
Study 21978765 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel consolidation therapy - 135 mg/m² every 28 days for ≤ 12 months, for patients with complete response (CR).
Number of subjects: 919
Study 21978765 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent crossover therapy for patients without CR, at induction doses/schedules until CR, disease progression (PD), or unacceptable toxicity.
Number of subjects: 919
Study 18547152 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cartridge lidocaine/epinephrine followed after 30 minutes by 1 cartridge phentolamine (1L1P)
Number of subjects: 16
Study 18547152 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cartridge phentolamine administered intravenously (1Piv)
Number of subjects: 16
Study 18547152 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cartridges lidocaine/epinephrine followed after 30 minutes by 2 cartridges phentolamine (4L2P)
Number of subjects: 16
Study 18547152 — intervention group
Group type: COMPARATOR
Intervention: 4 cartridges lidocaine/epinephrine followed by no phentolamine (4L)
Number of subjects: 16
Study 18547152 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of pharmacokinetic parameters for phentolamine, lidocaine, and epinephrine
Number of subjects: 16
Study 16939026 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 11mm distance
Number of subjects: 60
Study 16939026 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 12mm distance
Number of subjects: 60
Study 16939026 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 14mm distance
Number of subjects: 60
Study 16939026 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 16mm distance
Number of subjects: 60
Study 16939026 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (80mJ/2Hz) for 20s at 17mm distance
Number of subjects: 60
Study 16939026 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid application for 15 seconds (control group)
Number of subjects: 60
Study 12559677 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine
Number of subjects: 68
Study 12559677 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 68
Study 11041584 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Number of subjects: 96
Study 11041584 — intervention group
Group type: COMPARATOR
Intervention: Home exercises
Number of subjects: 96
Study 11041584 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 96
Study 9124194 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and filgrastim (5 microg/kg/day s.c.)
Number of subjects: 24
Study 9124194 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 24
Study 9124194 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and filgrastim (level 3: day 4 to day 7 and day 10 to day 13)
Number of subjects: 24
Study 9124194 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and filgrastim
Number of subjects: 24
Study 8438597 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplements of 26 ml water/kg body weight and 0.16 g sodium chloride/kg body weight during hypokinesia
Number of subjects: 18
Study 8438597 — intervention group
Group type: COMPARATOR
Intervention: Continuous restriction of motor activity without supplementation
Number of subjects: 18
Study 8438597 — intervention group
Group type: COMPARATOR
Intervention: Normal ambulatory life (control subjects)
Number of subjects: 18
Study 3462335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin administration in 8 SAD patients
Number of subjects: 34
Study 3462335 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta-adrenergic blocker) in 19 SAD patients
Number of subjects: 34
Study 3462335 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy in 7 SAD patients
Number of subjects: 34